ArticleJournal of virology2000
A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Engineering multiple levels of specificity in an RNA viral vector.Nature communications · 2026Article
- Postexit surface engineering of retroviral/lentiviral vectors.BioMed research international · 2013Review
- Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.Journal of virology · 2010Article
- Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.Retrovirology · 2010Article
- Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.Cancer gene therapy · 2009Article
- Imaging individual retroviral fusion events: from hemifusion to pore formation and growth.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Reconstitution of retroviral fusion and uncoating in a cell-free system.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Low pH is required for avian sarcoma and leukosis virus Env-induced hemifusion and fusion pore formation but not for pore growth.Journal of virology · 2004Article
- Two retroviral entry pathways distinguished by lipid raft association of the viral receptor and differences in viral infectivity.Journal of virology · 2003Article
- Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.Journal of virology · 2002Article
- A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.Journal of virology · 2002Article
- Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors.Gene therapy · 2001Article
- Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
We have previously described an approach that employs retroviral receptor-ligand bridge proteins to target retroviral vectors to specific cell types. To determine whether targeted retroviral entry can also be achieved using a retroviral receptor-single-chain antibody bridge protein, the TVA-MR1 fusion protein was generated. TVA-MR1 is comprised of the extracellular domain of the TVA receptor for subgroup A avian leukosis viruses (ALV-A), fused to the MR1 single-chain antibody that binds specifically to EGFRvIII, a tumor-specific form of the epidermal growth factor receptor. We show that TVA-MR1 binds specifically to a murine version of EGFRvIII and promotes ALV-A entry selectively into cells that express this cell surface marker. These studies demonstrate that it is possible to target retroviral vectors to specific cell types through the use of a retroviral receptor-single-chain antibody fusion protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.